SARS CoV-2 infection among patients using immunomodulatory therapies.
Identifieur interne : 000177 ( Main/Exploration ); précédent : 000176; suivant : 000178SARS CoV-2 infection among patients using immunomodulatory therapies.
Auteurs : Kevin L. Winthrop [États-Unis] ; Amanda E. Brunton [États-Unis] ; Susan Beekmann [États-Unis] ; Philip Polgreen [États-Unis] ; John Baddley [États-Unis] ; Kenneth G. Saag [États-Unis] ; Cassandra Calabrese [États-Unis] ; Leonard Calabrese [États-Unis] ; Philip C. Robinson [Australie] ; Zachary S. Wallace [États-Unis] ; Jeffrey R. Curtis [États-Unis]Source :
- Annals of the rheumatic diseases [ 1468-2060 ] ; 2021.
Descripteurs français
- KwdFr :
- Adolescent (MeSH), Adulte (MeSH), Adulte d'âge moyen (MeSH), Antibactériens (usage thérapeutique), Anticorps monoclonaux humanisés (usage thérapeutique), Antienzymes (usage thérapeutique), Antirhumatismaux (usage thérapeutique), Azithromycine (usage thérapeutique), Enquêtes et questionnaires (MeSH), Femelle (MeSH), Glucocorticoïdes (usage thérapeutique), Hospitalisation (MeSH), Humains (MeSH), Hydroxychloroquine (usage thérapeutique), Immunomodulation (MeSH), Immunosuppresseurs (usage thérapeutique), Inhibiteurs des Janus kinases (usage thérapeutique), Jeune adulte (MeSH), Maladies auto-immunes (complications), Maladies auto-immunes (traitement médicamenteux), Maladies inflammatoires intestinales (complications), Maladies inflammatoires intestinales (traitement médicamenteux), Mâle (MeSH), Polyarthrite rhumatoïde (complications), Polyarthrite rhumatoïde (traitement médicamenteux), Produits biologiques (usage thérapeutique), Sarcoïdose (complications), Sarcoïdose (traitement médicamenteux), Sujet âgé (MeSH), Sujet âgé de 80 ans ou plus (MeSH), Unités de soins intensifs (MeSH), Ventilation artificielle (MeSH).
- MESH :
- traitement médicamenteux : Maladies auto-immunes, Maladies inflammatoires intestinales, Polyarthrite rhumatoïde, Sarcoïdose.
- usage thérapeutique : Antibactériens, Anticorps monoclonaux humanisés, Antienzymes, Antirhumatismaux, Azithromycine, Glucocorticoïdes, Hydroxychloroquine, Immunosuppresseurs, Inhibiteurs des Janus kinases, Maladies auto-immunes, Maladies inflammatoires intestinales, Polyarthrite rhumatoïde, Produits biologiques, Sarcoïdose.
- Adolescent, Adulte, Adulte d'âge moyen, Enquêtes et questionnaires, Femelle, Hospitalisation, Humains, Immunomodulation, Jeune adulte, Mâle, Sujet âgé, Sujet âgé de 80 ans ou plus, Unités de soins intensifs, Ventilation artificielle.
English descriptors
- KwdEn :
- Adolescent (MeSH), Adult (MeSH), Aged (MeSH), Aged, 80 and over (MeSH), Anti-Bacterial Agents (therapeutic use), Antibodies, Monoclonal, Humanized (therapeutic use), Antirheumatic Agents (therapeutic use), Arthritis, Rheumatoid (complications), Arthritis, Rheumatoid (drug therapy), Autoimmune Diseases (complications), Autoimmune Diseases (drug therapy), Azithromycin (therapeutic use), Biological Products (therapeutic use), COVID-19 (complications), COVID-19 (drug therapy), COVID-19 (mortality), COVID-19 (therapy), Enzyme Inhibitors (therapeutic use), Female (MeSH), Glucocorticoids (therapeutic use), Hospitalization (MeSH), Humans (MeSH), Hydroxychloroquine (therapeutic use), Immunomodulation (MeSH), Immunosuppressive Agents (therapeutic use), Inflammatory Bowel Diseases (complications), Inflammatory Bowel Diseases (drug therapy), Intensive Care Units (MeSH), Janus Kinase Inhibitors (therapeutic use), Male (MeSH), Middle Aged (MeSH), Respiration, Artificial (MeSH), SARS-CoV-2 (MeSH), Sarcoidosis (complications), Sarcoidosis (drug therapy), Surveys and Questionnaires (MeSH), Tumor Necrosis Factor Inhibitors (therapeutic use), Young Adult (MeSH).
- MESH :
- chemical , therapeutic use : Anti-Bacterial Agents, Antibodies, Monoclonal, Humanized, Antirheumatic Agents, Azithromycin, Biological Products, Enzyme Inhibitors, Glucocorticoids, Hydroxychloroquine, Immunosuppressive Agents, Janus Kinase Inhibitors, Tumor Necrosis Factor Inhibitors.
- complications : Arthritis, Rheumatoid, Autoimmune Diseases, COVID-19, Inflammatory Bowel Diseases, Sarcoidosis.
- drug therapy : Arthritis, Rheumatoid, Autoimmune Diseases, COVID-19, Inflammatory Bowel Diseases, Sarcoidosis.
- mortality : COVID-19.
- therapy : COVID-19.
- Adolescent, Adult, Aged, Aged, 80 and over, Female, Hospitalization, Humans, Immunomodulation, Intensive Care Units, Male, Middle Aged, Respiration, Artificial, SARS-CoV-2, Surveys and Questionnaires, Young Adult.
DOI: 10.1136/annrheumdis-2020-218580
PubMed: 32759259
Affiliations:
- Australie, États-Unis
- Alabama, Iowa, Maryland, Massachusetts, Ohio, Oregon
- Portland
- Université des sciences et de la médecine de l'Oregon
Links toward previous steps (curation, corpus...)
Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">SARS CoV-2 infection among patients using immunomodulatory therapies.</title><author><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name><affiliation wicri:level="4"><nlm:affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA winthrop@ohsu.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>School of Public Health, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author><author><name sortKey="Brunton, Amanda E" sort="Brunton, Amanda E" uniqKey="Brunton A" first="Amanda E" last="Brunton">Amanda E. Brunton</name><affiliation wicri:level="4"><nlm:affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Public Health, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author><author><name sortKey="Beekmann, Susan" sort="Beekmann, Susan" uniqKey="Beekmann S" first="Susan" last="Beekmann">Susan Beekmann</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa</wicri:regionArea><placeName><region type="state">Iowa</region></placeName></affiliation></author><author><name sortKey="Polgreen, Philip" sort="Polgreen, Philip" uniqKey="Polgreen P" first="Philip" last="Polgreen">Philip Polgreen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa</wicri:regionArea><placeName><region type="state">Iowa</region></placeName></affiliation></author><author><name sortKey="Baddley, John" sort="Baddley, John" uniqKey="Baddley J" first="John" last="Baddley">John Baddley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G" last="Saag">Kenneth G. Saag</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Calabrese, Cassandra" sort="Calabrese, Cassandra" uniqKey="Calabrese C" first="Cassandra" last="Calabrese">Cassandra Calabrese</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Calabrese, Leonard" sort="Calabrese, Leonard" uniqKey="Calabrese L" first="Leonard" last="Calabrese">Leonard Calabrese</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2021">2021</date><idno type="RBID">pubmed:32759259</idno><idno type="pmid">32759259</idno><idno type="doi">10.1136/annrheumdis-2020-218580</idno><idno type="wicri:Area/Main/Corpus">000F67</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Corpus" wicri:corpus="PubMed">000F67</idno><idno type="wicri:Area/Main/Curation">000F67</idno><idno type="wicri:explorRef" wicri:stream="Main" wicri:step="Curation">000F67</idno><idno type="wicri:Area/Main/Exploration">000F67</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">SARS CoV-2 infection among patients using immunomodulatory therapies.</title><author><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name><affiliation wicri:level="4"><nlm:affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA winthrop@ohsu.edu.</nlm:affiliation><country wicri:rule="url">États-Unis</country><wicri:regionArea>School of Public Health, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation><affiliation wicri:level="4"><nlm:affiliation>Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author><author><name sortKey="Brunton, Amanda E" sort="Brunton, Amanda E" uniqKey="Brunton A" first="Amanda E" last="Brunton">Amanda E. Brunton</name><affiliation wicri:level="4"><nlm:affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>School of Public Health, Oregon Health & Science University, Portland, Oregon</wicri:regionArea><placeName><region type="state">Oregon</region><settlement type="city">Portland</settlement></placeName><orgName type="university">Université des sciences et de la médecine de l'Oregon</orgName></affiliation></author><author><name sortKey="Beekmann, Susan" sort="Beekmann, Susan" uniqKey="Beekmann S" first="Susan" last="Beekmann">Susan Beekmann</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa</wicri:regionArea><placeName><region type="state">Iowa</region></placeName></affiliation></author><author><name sortKey="Polgreen, Philip" sort="Polgreen, Philip" uniqKey="Polgreen P" first="Philip" last="Polgreen">Philip Polgreen</name><affiliation wicri:level="2"><nlm:affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa</wicri:regionArea><placeName><region type="state">Iowa</region></placeName></affiliation></author><author><name sortKey="Baddley, John" sort="Baddley, John" uniqKey="Baddley J" first="John" last="Baddley">John Baddley</name><affiliation wicri:level="2"><nlm:affiliation>Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland</wicri:regionArea><placeName><region type="state">Maryland</region></placeName></affiliation></author><author><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G" last="Saag">Kenneth G. Saag</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author><author><name sortKey="Calabrese, Cassandra" sort="Calabrese, Cassandra" uniqKey="Calabrese C" first="Cassandra" last="Calabrese">Cassandra Calabrese</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Calabrese, Leonard" sort="Calabrese, Leonard" uniqKey="Calabrese L" first="Leonard" last="Calabrese">Leonard Calabrese</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio</wicri:regionArea><placeName><region type="state">Ohio</region></placeName></affiliation></author><author><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name><affiliation wicri:level="1"><nlm:affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.</nlm:affiliation><country xml:lang="fr">Australie</country><wicri:regionArea>Faculty of Medicine, The University of Queensland, Herston, Queensland</wicri:regionArea><wicri:noRegion>Queensland</wicri:noRegion></affiliation></author><author><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><affiliation wicri:level="2"><nlm:affiliation>Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts</wicri:regionArea><placeName><region type="state">Massachusetts</region></placeName></affiliation></author><author><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><affiliation wicri:level="2"><nlm:affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</nlm:affiliation><country xml:lang="fr">États-Unis</country><wicri:regionArea>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama</wicri:regionArea><placeName><region type="state">Alabama</region></placeName></affiliation></author></analytic><series><title level="j">Annals of the rheumatic diseases</title><idno type="eISSN">1468-2060</idno><imprint><date when="2021" type="published">2021</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Adolescent (MeSH)</term><term>Adult (MeSH)</term><term>Aged (MeSH)</term><term>Aged, 80 and over (MeSH)</term><term>Anti-Bacterial Agents (therapeutic use)</term><term>Antibodies, Monoclonal, Humanized (therapeutic use)</term><term>Antirheumatic Agents (therapeutic use)</term><term>Arthritis, Rheumatoid (complications)</term><term>Arthritis, Rheumatoid (drug therapy)</term><term>Autoimmune Diseases (complications)</term><term>Autoimmune Diseases (drug therapy)</term><term>Azithromycin (therapeutic use)</term><term>Biological Products (therapeutic use)</term><term>COVID-19 (complications)</term><term>COVID-19 (drug therapy)</term><term>COVID-19 (mortality)</term><term>COVID-19 (therapy)</term><term>Enzyme Inhibitors (therapeutic use)</term><term>Female (MeSH)</term><term>Glucocorticoids (therapeutic use)</term><term>Hospitalization (MeSH)</term><term>Humans (MeSH)</term><term>Hydroxychloroquine (therapeutic use)</term><term>Immunomodulation (MeSH)</term><term>Immunosuppressive Agents (therapeutic use)</term><term>Inflammatory Bowel Diseases (complications)</term><term>Inflammatory Bowel Diseases (drug therapy)</term><term>Intensive Care Units (MeSH)</term><term>Janus Kinase Inhibitors (therapeutic use)</term><term>Male (MeSH)</term><term>Middle Aged (MeSH)</term><term>Respiration, Artificial (MeSH)</term><term>SARS-CoV-2 (MeSH)</term><term>Sarcoidosis (complications)</term><term>Sarcoidosis (drug therapy)</term><term>Surveys and Questionnaires (MeSH)</term><term>Tumor Necrosis Factor Inhibitors (therapeutic use)</term><term>Young Adult (MeSH)</term></keywords><keywords scheme="KwdFr" xml:lang="fr"><term>Adolescent (MeSH)</term><term>Adulte (MeSH)</term><term>Adulte d'âge moyen (MeSH)</term><term>Antibactériens (usage thérapeutique)</term><term>Anticorps monoclonaux humanisés (usage thérapeutique)</term><term>Antienzymes (usage thérapeutique)</term><term>Antirhumatismaux (usage thérapeutique)</term><term>Azithromycine (usage thérapeutique)</term><term>Enquêtes et questionnaires (MeSH)</term><term>Femelle (MeSH)</term><term>Glucocorticoïdes (usage thérapeutique)</term><term>Hospitalisation (MeSH)</term><term>Humains (MeSH)</term><term>Hydroxychloroquine (usage thérapeutique)</term><term>Immunomodulation (MeSH)</term><term>Immunosuppresseurs (usage thérapeutique)</term><term>Inhibiteurs des Janus kinases (usage thérapeutique)</term><term>Jeune adulte (MeSH)</term><term>Maladies auto-immunes (complications)</term><term>Maladies auto-immunes (traitement médicamenteux)</term><term>Maladies inflammatoires intestinales (complications)</term><term>Maladies inflammatoires intestinales (traitement médicamenteux)</term><term>Mâle (MeSH)</term><term>Polyarthrite rhumatoïde (complications)</term><term>Polyarthrite rhumatoïde (traitement médicamenteux)</term><term>Produits biologiques (usage thérapeutique)</term><term>Sarcoïdose (complications)</term><term>Sarcoïdose (traitement médicamenteux)</term><term>Sujet âgé (MeSH)</term><term>Sujet âgé de 80 ans ou plus (MeSH)</term><term>Unités de soins intensifs (MeSH)</term><term>Ventilation artificielle (MeSH)</term></keywords><keywords scheme="MESH" type="chemical" qualifier="therapeutic use" xml:lang="en"><term>Anti-Bacterial Agents</term><term>Antibodies, Monoclonal, Humanized</term><term>Antirheumatic Agents</term><term>Azithromycin</term><term>Biological Products</term><term>Enzyme Inhibitors</term><term>Glucocorticoids</term><term>Hydroxychloroquine</term><term>Immunosuppressive Agents</term><term>Janus Kinase Inhibitors</term><term>Tumor Necrosis Factor Inhibitors</term></keywords><keywords scheme="MESH" qualifier="complications" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Autoimmune Diseases</term><term>COVID-19</term><term>Inflammatory Bowel Diseases</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="drug therapy" xml:lang="en"><term>Arthritis, Rheumatoid</term><term>Autoimmune Diseases</term><term>COVID-19</term><term>Inflammatory Bowel Diseases</term><term>Sarcoidosis</term></keywords><keywords scheme="MESH" qualifier="mortality" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>COVID-19</term></keywords><keywords scheme="MESH" qualifier="traitement médicamenteux" xml:lang="fr"><term>Maladies auto-immunes</term><term>Maladies inflammatoires intestinales</term><term>Polyarthrite rhumatoïde</term><term>Sarcoïdose</term></keywords><keywords scheme="MESH" qualifier="usage thérapeutique" xml:lang="fr"><term>Antibactériens</term><term>Anticorps monoclonaux humanisés</term><term>Antienzymes</term><term>Antirhumatismaux</term><term>Azithromycine</term><term>Glucocorticoïdes</term><term>Hydroxychloroquine</term><term>Immunosuppresseurs</term><term>Inhibiteurs des Janus kinases</term><term>Maladies auto-immunes</term><term>Maladies inflammatoires intestinales</term><term>Polyarthrite rhumatoïde</term><term>Produits biologiques</term><term>Sarcoïdose</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Adolescent</term><term>Adult</term><term>Aged</term><term>Aged, 80 and over</term><term>Female</term><term>Hospitalization</term><term>Humans</term><term>Immunomodulation</term><term>Intensive Care Units</term><term>Male</term><term>Middle Aged</term><term>Respiration, Artificial</term><term>SARS-CoV-2</term><term>Surveys and Questionnaires</term><term>Young Adult</term></keywords><keywords scheme="MESH" xml:lang="fr"><term>Adolescent</term><term>Adulte</term><term>Adulte d'âge moyen</term><term>Enquêtes et questionnaires</term><term>Femelle</term><term>Hospitalisation</term><term>Humains</term><term>Immunomodulation</term><term>Jeune adulte</term><term>Mâle</term><term>Sujet âgé</term><term>Sujet âgé de 80 ans ou plus</term><term>Unités de soins intensifs</term><term>Ventilation artificielle</term></keywords></textClass></profileDesc></teiHeader></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">32759259</PMID><DateCompleted><Year>2021</Year><Month>01</Month><Day>22</Day></DateCompleted><DateRevised><Year>2021</Year><Month>01</Month><Day>22</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1468-2060</ISSN><JournalIssue CitedMedium="Internet"><Volume>80</Volume><Issue>2</Issue><PubDate><Year>2021</Year><Month>02</Month></PubDate></JournalIssue><Title>Annals of the rheumatic diseases</Title><ISOAbbreviation>Ann Rheum Dis</ISOAbbreviation></Journal><ArticleTitle>SARS CoV-2 infection among patients using immunomodulatory therapies.</ArticleTitle><Pagination><MedlinePgn>269-271</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1136/annrheumdis-2020-218580</ELocationID><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Winthrop</LastName><ForeName>Kevin L</ForeName><Initials>KL</Initials><Identifier Source="ORCID">0000-0002-3892-6947</Identifier><AffiliationInfo><Affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA winthrop@ohsu.edu.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Division of Infectious Diseases, Oregon Health & Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunton</LastName><ForeName>Amanda E</ForeName><Initials>AE</Initials><AffiliationInfo><Affiliation>School of Public Health, Oregon Health & Science University, Portland, Oregon, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Beekmann</LastName><ForeName>Susan</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Polgreen</LastName><ForeName>Philip</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, University of Iowa Carver College of Medicine, Iowa City, Iowa, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Baddley</LastName><ForeName>John</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, University of Maryland School of Medicine, Baltimore, Maryland, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Saag</LastName><ForeName>Kenneth G</ForeName><Initials>KG</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Cassandra</ForeName><Initials>C</Initials><Identifier Source="ORCID">0000-0002-8773-7739</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Calabrese</LastName><ForeName>Leonard</ForeName><Initials>L</Initials><Identifier Source="ORCID">0000-0002-1789-4923</Identifier><AffiliationInfo><Affiliation>Division of Rheumatology, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Philip C</ForeName><Initials>PC</Initials><Identifier Source="ORCID">0000-0002-3156-3418</Identifier><AffiliationInfo><Affiliation>Faculty of Medicine, The University of Queensland, Herston, Queensland, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wallace</LastName><ForeName>Zachary S</ForeName><Initials>ZS</Initials><AffiliationInfo><Affiliation>Division of Rheumatology, Allergy and Immunology, Massachusetts General Hospital and Harvard Medical School, Boston, Massachusetts, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Curtis</LastName><ForeName>Jeffrey R</ForeName><Initials>JR</Initials><AffiliationInfo><Affiliation>Division of Clinical Immunology and Rheumatology, University of Alabama at Birmingham, Birmingham, Alabama, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>COVID-19 Study Team</CollectiveName></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR002537</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016422">Letter</PublicationType><PublicationType UI="D052061">Research Support, N.I.H., Extramural</PublicationType><PublicationType UI="D013486">Research Support, U.S. Gov't, Non-P.H.S.</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2020</Year><Month>08</Month><Day>05</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Ann Rheum Dis</MedlineTA><NlmUniqueID>0372355</NlmUniqueID><ISSNLinking>0003-4967</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000900">Anti-Bacterial Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D061067">Antibodies, Monoclonal, Humanized</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018501">Antirheumatic Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D001688">Biological Products</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D004791">Enzyme Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D005938">Glucocorticoids</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D007166">Immunosuppressive Agents</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000075242">Janus Kinase Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D000079424">Tumor Necrosis Factor Inhibitors</NameOfSubstance></Chemical><Chemical><RegistryNumber>4QWG6N8QKH</RegistryNumber><NameOfSubstance UI="D006886">Hydroxychloroquine</NameOfSubstance></Chemical><Chemical><RegistryNumber>83905-01-5</RegistryNumber><NameOfSubstance UI="D017963">Azithromycin</NameOfSubstance></Chemical><Chemical><RegistryNumber>I031V2H011</RegistryNumber><NameOfSubstance UI="C502936">tocilizumab</NameOfSubstance></Chemical></ChemicalList><SupplMeshList><SupplMeshName Type="Protocol" UI="C000705127">COVID-19 drug treatment</SupplMeshName></SupplMeshList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000293" MajorTopicYN="N">Adolescent</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000369" MajorTopicYN="N">Aged, 80 and over</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000900" MajorTopicYN="N">Anti-Bacterial Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D061067" MajorTopicYN="N">Antibodies, Monoclonal, Humanized</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D018501" MajorTopicYN="N">Antirheumatic Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001172" MajorTopicYN="N">Arthritis, Rheumatoid</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001327" MajorTopicYN="N">Autoimmune Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="Y">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D017963" MajorTopicYN="N">Azithromycin</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D001688" MajorTopicYN="N">Biological Products</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="N">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004791" MajorTopicYN="N">Enzyme Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005938" MajorTopicYN="N">Glucocorticoids</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006760" MajorTopicYN="N">Hospitalization</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006886" MajorTopicYN="N">Hydroxychloroquine</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D056747" MajorTopicYN="N">Immunomodulation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007166" MajorTopicYN="N">Immunosuppressive Agents</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="Y">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015212" MajorTopicYN="N">Inflammatory Bowel Diseases</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000075242" MajorTopicYN="N">Janus Kinase Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012121" MajorTopicYN="N">Respiration, Artificial</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012507" MajorTopicYN="N">Sarcoidosis</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000188" MajorTopicYN="N">drug therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D011795" MajorTopicYN="N">Surveys and Questionnaires</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000079424" MajorTopicYN="N">Tumor Necrosis Factor Inhibitors</DescriptorName><QualifierName UI="Q000627" MajorTopicYN="N">therapeutic use</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D055815" MajorTopicYN="N">Young Adult</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="Y">arthritis</Keyword><Keyword MajorTopicYN="Y">autoimmune diseases</Keyword><Keyword MajorTopicYN="Y">biological therapy</Keyword><Keyword MajorTopicYN="Y">rheumatoid</Keyword></KeywordList><CoiStatement>Competing interests: KLW reports personal fees from Pfizer, AbbVie, Union Chimique Belge (UCB), Eli Lilly & Company, Galapagos, GlaxoSmithKline (GSK), Roche, Gilead and reports research grants from BMS, Pfizer outside the submitted work. AB and SB have no potential conflicts of interest. PP reports grants from Centers for Disease Control and Prevention, grants from National Center For Advancing Translational Sciences, during the conduct of the study; non-financial support from 3M, personal fees from Eli Lily, outside the submitted work. JB reports personal fees from Pfizer, Lilly, R-Pharm and Viela Bio outside the submitted work. KGS reports grants and personal fees from Amgen, personal fees from Sanofi/Genzyme, personal fees from Gilead, outside the submitted work. CC reports personal fees from AbbVie and is a member of the speakers’ bureau for Sanofi-Regeneron outside the submitted work. LC reports personal fees from Genentech, personal fees from GMS, personal fees from GSK, personal fees from AbbVie, personal fees from Janssen, personal fees from Sanofi, personal fees from Gilead, personal fees from Kiniksa, personal fees from UCB, outside the submitted work. PCR reports personal fees and non-financial support from Roche, personal fees from Abbvie, grants and personal fees from Janssen, grants and personal fees from Novartis, non-financial support from BMS, personal fees from Eli Lilly, personal fees from Pfizer, grants and personal fees from UCB, outside the submitted work. ZSW reports research grants from NIH/NIAMS (K23AR073334 and L30 AR070520) and Bristol-Myers Squibb outside the submitted work. JRC reports grants and personal fees from AbbVie, grants and personal fees from Amgen, grants and personal fees from BMS, grants and personal fees from Corrona, grants and personal fees from Eli Lilly, grants and personal fees from Janssen, grants and personal fees from Myriad, grants and personal fees from Pfizer, grants and personal fees from Regeneron, grants and personal fees from Roche, grants and personal fees from UCB, outside the submitted work.</CoiStatement><InvestigatorList><Investigator ValidYN="Y"><LastName>Brady</LastName><ForeName>Adam</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ovalle</LastName><ForeName>Anais</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>O'Donnell</LastName><ForeName>Anne</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Malik</LastName><ForeName>Anuj</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Rashid</LastName><ForeName>Ayesha</ForeName><Initials>A</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poole</LastName><ForeName>Bryan</ForeName><Initials>B</Initials></Investigator><Investigator ValidYN="Y"><LastName>Field</LastName><ForeName>Carey J</ForeName><Initials>CJ</Initials></Investigator><Investigator ValidYN="Y"><LastName>Graber</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Palma</LastName><ForeName>Christopher</ForeName><Initials>C</Initials></Investigator><Investigator ValidYN="Y"><LastName>Brieff</LastName><ForeName>David</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Pattanaik</LastName><ForeName>Debendra</ForeName><Initials>D</Initials></Investigator><Investigator ValidYN="Y"><LastName>Riedo</LastName><ForeName>Francis</ForeName><Initials>F</Initials></Investigator><Investigator ValidYN="Y"><LastName>Helou</LastName><ForeName>Guy El</ForeName><Initials>GE</Initials></Investigator><Investigator ValidYN="Y"><LastName>Zembrzuska</LastName><ForeName>Hanna</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Poonawala</LastName><ForeName>Husain</ForeName><Initials>H</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cheah</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kay</LastName><ForeName>Jonathan</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Lucar</LastName><ForeName>Jose A</ForeName><Initials>JA</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ali</LastName><ForeName>Juzar</ForeName><Initials>J</Initials></Investigator><Investigator ValidYN="Y"><LastName>Shah</LastName><ForeName>Kairav</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Cleveland</LastName><ForeName>Kerry</ForeName><Initials>K</Initials></Investigator><Investigator ValidYN="Y"><LastName>Howard</LastName><ForeName>Leigh M</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Raymundo</LastName><ForeName>Luis Marcos</ForeName><Initials>LM</Initials></Investigator><Investigator ValidYN="Y"><LastName>Wongskhaluang</LastName><ForeName>Marjorie</ForeName><Initials>M</Initials></Investigator><Investigator ValidYN="Y"><LastName>Liu</LastName><ForeName>Nancy</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Hartog</LastName><ForeName>Nicholas</ForeName><Initials>N</Initials></Investigator><Investigator ValidYN="Y"><LastName>Holland Alday</LastName><ForeName>P</ForeName><Initials>P</Initials></Investigator><Investigator ValidYN="Y"><LastName>Orscheln</LastName><ForeName>Rachel</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Berdel</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kumar</LastName><ForeName>Rebecca</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Striker</LastName><ForeName>Robert</ForeName><Initials>R</Initials></Investigator><Investigator ValidYN="Y"><LastName>Mazumder</LastName><ForeName>Shirin</ForeName><Initials>S</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kobayashi</LastName><ForeName>Takaaki</ForeName><Initials>T</Initials></Investigator><Investigator ValidYN="Y"><LastName>Kak</LastName><ForeName>Vivek</ForeName><Initials>V</Initials></Investigator><Investigator ValidYN="Y"><LastName>Chang</LastName><ForeName>Wun-Ling</ForeName><Initials>WL</Initials></Investigator><Investigator ValidYN="Y"><LastName>Ali</LastName><ForeName>Yousaf</ForeName><Initials>Y</Initials></Investigator></InvestigatorList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2020</Year><Month>07</Month><Day>14</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2020</Year><Month>07</Month><Day>22</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2020</Year><Month>07</Month><Day>25</Day></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2021</Year><Month>1</Month><Day>23</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2020</Year><Month>8</Month><Day>8</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">32759259</ArticleId><ArticleId IdType="pii">annrheumdis-2020-218580</ArticleId><ArticleId IdType="doi">10.1136/annrheumdis-2020-218580</ArticleId></ArticleIdList></PubmedData></pubmed><affiliations><list><country><li>Australie</li><li>États-Unis</li></country><region><li>Alabama</li><li>Iowa</li><li>Maryland</li><li>Massachusetts</li><li>Ohio</li><li>Oregon</li></region><settlement><li>Portland</li></settlement><orgName><li>Université des sciences et de la médecine de l'Oregon</li></orgName></list><tree><country name="États-Unis"><region name="Oregon"><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name></region><name sortKey="Baddley, John" sort="Baddley, John" uniqKey="Baddley J" first="John" last="Baddley">John Baddley</name><name sortKey="Beekmann, Susan" sort="Beekmann, Susan" uniqKey="Beekmann S" first="Susan" last="Beekmann">Susan Beekmann</name><name sortKey="Brunton, Amanda E" sort="Brunton, Amanda E" uniqKey="Brunton A" first="Amanda E" last="Brunton">Amanda E. Brunton</name><name sortKey="Calabrese, Cassandra" sort="Calabrese, Cassandra" uniqKey="Calabrese C" first="Cassandra" last="Calabrese">Cassandra Calabrese</name><name sortKey="Calabrese, Leonard" sort="Calabrese, Leonard" uniqKey="Calabrese L" first="Leonard" last="Calabrese">Leonard Calabrese</name><name sortKey="Curtis, Jeffrey R" sort="Curtis, Jeffrey R" uniqKey="Curtis J" first="Jeffrey R" last="Curtis">Jeffrey R. Curtis</name><name sortKey="Polgreen, Philip" sort="Polgreen, Philip" uniqKey="Polgreen P" first="Philip" last="Polgreen">Philip Polgreen</name><name sortKey="Saag, Kenneth G" sort="Saag, Kenneth G" uniqKey="Saag K" first="Kenneth G" last="Saag">Kenneth G. Saag</name><name sortKey="Wallace, Zachary S" sort="Wallace, Zachary S" uniqKey="Wallace Z" first="Zachary S" last="Wallace">Zachary S. Wallace</name><name sortKey="Winthrop, Kevin L" sort="Winthrop, Kevin L" uniqKey="Winthrop K" first="Kevin L" last="Winthrop">Kevin L. Winthrop</name></country><country name="Australie"><noRegion><name sortKey="Robinson, Philip C" sort="Robinson, Philip C" uniqKey="Robinson P" first="Philip C" last="Robinson">Philip C. Robinson</name></noRegion></country></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/CovidChloroV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 000177 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 000177 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= CovidChloroV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= pubmed:32759259
|texte= SARS CoV-2 infection among patients using immunomodulatory therapies.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/Main/Exploration/RBID.i -Sk "pubmed:32759259" \
| HfdSelect -Kh $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd \
| NlmPubMed2Wicri -a CovidChloroV1
| This area was generated with Dilib version V0.6.38. |  |